Sign In
Buy ITRM
$0.0300
+0 (+0%)
At Close: Jun 03, 2026
Iterum Therapeutics to Present in Upcoming Investor Conferences
05:30pm, Friday, 19'th Feb 2021
DUBLIN, Ireland and CHICAGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics: Sulopenem Approval Decision In July Is Make Or Break
01:33pm, Friday, 12'th Feb 2021
After three missed endpoints in three pivotal trials, Iterum's antibiotic treatment Sulopenem displayed superiority over standard-of-care Cipro in uUTI patients with quinolone resistant pathogens. Ite
ITRM Stock Price Increases Over 15% Pre-Market: Why It Happened
07:45am, Thursday, 11'th Feb 2021
The stock price of Iterum Therapeutics PLC (NASDAQ: ITRM) is trading at over 15% pre-market. This is why it happened.
Iterum Therapeutics plc Announces Exercise of Underwriter's Option to Purchase Additional Ordinary Shares
06:40pm, Wednesday, 10'th Feb 2021
DUBLIN, Ireland and CHICAGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
ITRM Stock: 7 Things for Investors to Know About Iterum Therapeutics as Shares Surge
11:02am, Tuesday, 09'th Feb 2021
Iterum Therapeutics (ITRM) stock is taking off on Tuesday with heavy trading even without any news coming from the company. The post ITRM Stock: 7 Things for Investors to Know About Iterum Therapeutic
ITRM Stock Price Increases Over 60% Pre-Market
06:04am, Tuesday, 09'th Feb 2021
The stock price of Iterum Therapeutics PLC (NASDAQ: ITRM) is trading at over 60% pre-market today as of 5:50 AM ET. This is why it happened.
Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million
11:35pm, Wednesday, 03'rd Feb 2021
DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics plc Announces $10 Million Bought Deal Public Offering of Ordinary Shares
05:51pm, Wednesday, 03'rd Feb 2021
DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics Announces Collaboration with EVERSANA to Support Oral Sulopenem Launch
07:00am, Monday, 01'st Feb 2021
DUBLIN, Ireland and CHICAGO, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem
07:00am, Monday, 25'th Jan 2021
-- If approved, First Oral Penem in the U.S. and First New Oral Treatment for uUTIs in Over 20 Years -- -- PDUFA goal date of July 25, 2021 --
Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference
05:00pm, Wednesday, 06'th Jan 2021
DUBLIN, Ireland and CHICAGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics Announces Transition of Michael Dunne, M.D. to Strategic Advisor and Member of the Board of Directors
07:00am, Wednesday, 23'rd Dec 2020
--Dr. Dunne resigns as Chief Scientific Officer-- -- Steven Aronin, M.D., Senior Vice President and Head of Clinical Development, to lead Development and Regulatory Activities --
Iterum Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
05:00pm, Monday, 21'st Dec 2020
Trading on Nasdaq Capital Market is expected to begin on December 23, 2020 Trading on Nasdaq Capital Market is expected to begin on December 23, 2020
Bilayer tablet patent application could provide U.S. patent coverage for Iterum's commercial formulation through 2039, if granted Bilayer tablet patent application could provide U.S. patent coverage f
